Ariad stock options

Ariad ARIA Stock Will It Continue To Climb? CNA Finance

In a research report Wednesday, RBC analysts list Ariad Pharmaceuticals (ARIA), Spark Therapeutics (ONCE), Bio Marin Pharmaceutical (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular Therapies (ITCI), Tesaro (TSRO), Incyte (INCY) and Puma Biotechnology (PBYI) -- as well as Sarepta — as top takeover contenders, all on their late-stage or FDA-approved "blockbuster franchises." Sarepta stock rocketed 74% on Monday after the FDA approved its drug to treat Duchenne muscular dystrophy, the first drug approved to treat the rare disease. After the close, Sarepta announced plans to offer up to $225 million in stock to finance further trials, production and other drug efforts. Over the past 10 months, four biotech acquisitions valued at over $5 billion have been announced, RBC said, along with a smattering of smaller deals.

Harvey J. Berger M. D. -

It now costs $199,000 a year, before factoring in insurance or any discounts. When it was first approved in 2012, the drug cost $9,580 a month. Along the way, the drug has had some safety problems and actually got pulled off the market in 2013 by the FDA, but a few months later was reinstated with warnings about cardiovascular problems that may occur.

<u>Ariad</u> ARIA <u>Stock</u> Will It Continue To Climb? CNA Finance

Ariad Pharmaceuticals Appears To Be On The Brink Of Bankruptcy.

The deal is expected to be complete this coming February, offering Takeda a wide array of drugs and treatments related to hematology, as well as products to treat tumors.

Ariad Pharmaceuticals, Inc. NASDAQARIA quotes & news. - Google

) stock is having a field day as rumors regarding a buyout continue to swirl.

Ariad stock options:

Rating: 94 / 100

Overall: 90 Rates